Appropriate use of medicines is a critical tool for sustainable healthcare financing in Europe, but access and predictability of funding has to be improved. Market access is critical for ensuring that patients rapidly gain access to new treatments. Swift market access also helps companies sustain employment and continue discovery by providing a more rapid return on investment in research and development.
Today's challenges require a more stable and predictable competitive environment in which discovery can flourish. It would be a mistake to sacrifice the long-term benefits of medicine to meet immediate budget pressures.